PRJNA474747
Precision Medicine for Relapsed Multiple Myeloma Based on an Integrative Multi-Omics Approach
We have developed a novel computational platform for precision medicine of relapsed/refractory MM based on DNA and RNA sequencing and tested our approach in a pilot precision medicine clinical trial with 64 patients with relapsed/refractory MM.